Cheap drug combo may tame tough anemia

NCT ID NCT04324411

Terminated Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests a combination of two drugs, sirolimus and all-trans retinoic acid (ATRA), for people with autoimmune anemia that has not responded to standard treatments. Autoimmune anemia occurs when the immune system attacks red blood cells, causing fatigue and other symptoms. The study aims to see if this combination can improve response rates and reduce side effects compared to existing therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus and all-trans retinoic acid (ATRA)
What this could lead to: If it works, this combination could offer an effective, affordable treatment option for people with autoimmune anemia who have not responded to standard therapies.
What could go wrong: This is a Phase 4 trial, but the combination is new for this condition. Some patients may still not respond, and side effects like kidney issues or gum problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia Evans syndrome pure red-cell aplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE ANEMIA

Contacts and locations

Show contact details

Locations

Peking union medical college hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.